ethyl 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate | 241798-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate
• 英文别名: ethyl 1-(quinolin-5-yl)-5-cyclopropyl-1H-pyrazole-4-carboxylate；ethyl 5-cyclopropyl-1-quinolin-5-ylpyrazole-4-carboxylate
• CAS: 241798-48-1
• 化学式: C₁₈H₁₇N₃O₂
• 分子量: 307.352
• InChiKey: KDRWXCMGMPBUFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  483.5±35.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate 在 sodium hydroxide 、 氯化亚砜 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 Zoniporide; CP 597396; [1-(喹啉-5-基)-5-环丙基-1H-吡唑-4-甲酰基]胍
  参考文献：
  名称：

  Discovery of zoniporide: A potent and selective sodium–hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility

  摘要：

  Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compound are presented. The potency and selectivity of zoniporide may be due to the conformation that the molecule adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the molecule. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00059-2
• 作为产物：
  描述：

  乙基三甲基硅基丙二酸 在 正丁基锂 、 三乙胺 作用下， 以 乙醇 、 正己烷 为溶剂， 反应 21.25h， 生成 ethyl 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  Discovery of zoniporide: A potent and selective sodium–hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility

  摘要：

  Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compound are presented. The potency and selectivity of zoniporide may be due to the conformation that the molecule adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the molecule. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00059-2

文献信息

• [EN] COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSES POUR TRAITEMENT DES MALADIES CARDIO-VASCULAIRES
  申请人：PFIZER PROD INC

  公开号：WO2005079803A1

  公开（公告）日：2005-09-01

  Pharmaceutical compositions containing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors in combination with Ca 2+ overload inhibitors, and the use of such combination inhibitors to treat, for example, cardiovascular disease, such as ischemia, particularly, perioperative myocardial ischemic injury in mammals, including humans, are disclosed.

  含有钠-氢交换型1（NHE-1）抑制剂与Ca2+超载抑制剂的药物组合，以及利用这种组合抑制剂治疗心血管疾病（如缺血），特别是哺乳动物（包括人类）中的围手术期心肌缺血性损伤的用途被披露。
• [EN] N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA<br/>[FR] DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE TRAITEMENT DE L'ISCHEMIE
  申请人：PFIZER PRODUCTS INC.

  公开号：WO1999043663A1

  公开（公告）日：1999-09-02

  (EN) NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.(FR) L'invention porte sur des inhibiteurs du NHE-1, sur leurs procédés d'utilisation, et sur des préparations pharmaceutiques les contenant. Lesdits inhibiteurs servent à réduire les dommages tissulaires résultant de l'ischémie des tissus.

  NHE-1抑制剂，使用这种NHE-1抑制剂的方法以及含有这种NHE-1抑制剂的药物组合物。这些NHE-1抑制剂有助于减少组织缺血引起的组织损伤。
• N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
  申请人：Pfizer Inc.

  公开号：US20030149043A1

  公开（公告）日：2003-08-07

  NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

  NHE-1抑制剂，使用这种NHE-1抑制剂的方法以及含有这种NHE-1抑制剂的制药组合物。NHE-1抑制剂对于减少组织缺血引起的组织损伤是有用的。
• N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia
  申请人：Hamanaka Ernest S.

  公开号：US06974813B2

  公开（公告）日：2005-12-13

  NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

  NHE-1抑制剂，使用这种NHE-1抑制剂的方法以及包含这种NHE-1抑制剂的制药组合物。 NHE-1抑制剂对于减少组织缺血引起的组织损伤非常有用。
• N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia
  申请人：Pfizer Products Inc.

  公开号：EP1454902A1

  公开（公告）日：2004-09-08

  This invention relates to NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

  本发明涉及 NHE-1 抑制剂、使用这种 NHE-1 抑制剂的方法以及含有这种 NHE-1 抑制剂的药物组合物。NHE-1 抑制剂可用于减少组织缺血造成的组织损伤。